CPC A61K 35/17 (2013.01) [A61K 39/001126 (2018.08); A61K 39/001129 (2018.08); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 39/4631 (2023.05); A61P 35/00 (2018.01); C07K 16/28 (2013.01); C07K 16/2896 (2013.01); C07K 16/3061 (2013.01); C12N 5/0636 (2013.01); C12N 5/10 (2013.01); C12N 15/63 (2013.01); A61K 2039/505 (2013.01); C07K 16/30 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/56 (2013.01); C07K 2317/569 (2013.01); C07K 2317/76 (2013.01); C07K 2319/03 (2013.01)] | 19 Claims |
1. A T-cell genetically modified to express at least two distinct separate chimeric antigen receptors (CARs), wherein the first CAR comprises an antigen binding domain that binds specifically to CD138 and the second CAR comprises an antigen binding domain that binds specifically to CD38, wherein one of the CARs comprises an activation domain and is devoid of a costimulatory domain and the other CAR comprises a costimulatory domain and is devoid of an activation domain.
|